Government-Owned Inventions; Availability for Licensing; Correction, 64152 [2020-22370]
Download as PDF
64152
Federal Register / Vol. 85, No. 197 / Friday, October 9, 2020 / Notices
Dated: October 5, 2020.
Melanie J. Pantoja,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2020–22439 Filed 10–8–20; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Cancer Institute; Amended
Notice of Meeting
Notice is hereby given of a change in
the meeting of the National Cancer
Institute Special Emphasis Panel,
November 12, 2020, 10:00 a.m. to
November 12, 2020, 5:00 p.m., National
Cancer Institute Shady Grove, Rockville,
MD 20850 which was published in the
Federal Register on September 04, 2020,
85 FR 55308.
This notice is being amended to
change the meeting start time from
10:00 a.m. to 1:00 p.m. The meeting will
now be held from 1:00 p.m. to 5:00 p.m.
on November 12, 2020. The meeting is
closed to the public.
Dated: October 5, 2020.
Melanie J. Pantoja,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2020–22437 Filed 10–8–20; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Center for Complementary &
Integrative Health; Notice of Closed
Meeting
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended, notice is hereby given of the
following meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Center for
Complementary and Integrative Health
Special Emphasis Panel; Early Phase Clinical
Trials of Natural Products (NP).
Date: November 6, 2020.
VerDate Sep<11>2014
17:26 Oct 08, 2020
Jkt 253001
Time: 11:00 a.m. to 5:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: NIH, Democracy II, 6707 Democracy
Blvd., Bethesda, MD 20892 (Virtual Meeting).
Contact Person: Martina Schmidt, Ph.D.,
Chief, Office of Scientific Review, National
Center for Complementary & Integrative
Health, NIH, 6707 Democracy Blvd., Suite
401, Bethesda, MD 20892, 301–594–3456,
schmidma@mail.nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.213, Research and Training
in Complementary and Alternative Medicine,
National Institutes of Health, HHS)
Dated: October 6, 2020.
Ronald J. Livingston, Jr.,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2020–22438 Filed 10–8–20; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Government-Owned Inventions;
Availability for Licensing; Correction
AGENCY:
National Institutes of Health,
HHS.
ACTION:
Notice; correction.
The Department of Health and
Human Services, National Institutes of
Health published a Notice in the
Federal Register on October 1, 2020.
That Notice requires a correction in the
SUPPLEMENTARY INFORMATION section.
FOR FURTHER INFORMATION CONTACT:
Amy F. Petrik, Ph.D., licensing contact,
240–627–3721; amy.petrik@nih.gov.
Licensing information and copies of the
U.S. patent application may be obtained
by communicating with the licensing
contact at the Technology Transfer and
Intellectual Property Office, National
Institute of Allergy and Infectious
Diseases, 5601 Fishers Lane, Rockville,
MD 20852; tel. 301–496–2644. A signed
Confidential Disclosure Agreement will
be required to receive copies of
unpublished patent applications.
SUPPLEMENTARY INFORMATION:
SUMMARY:
Correction
In the Federal Register of October 1,
2020, in FR Doc. 2020–21708, on page
61961, as found within the
SUPPLEMENTARY INFORMATION section.
The title of the invention, currently
reads ‘‘Structure-Based Design of
SARS2–CoV–2 Spike Immunogens
Stabilized in the RBD-All Down
Conformation’’ and should read
‘‘Structure-Based Design of SARS–CoV–
2 Spike Immunogens Stabilized in the
RBD-All Down Conformation’’.
PO 00000
Frm 00045
Fmt 4703
Sfmt 4703
Dated: October 5, 2020.
Daniel R Hernandez,
Federal Register Officer, National Institutes
of Health.
[FR Doc. 2020–22370 Filed 10–8–20; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Notice of Diabetes Mellitus Interagency
Coordinating Committee Meeting
AGENCY:
National Institutes of Health,
HHS.
ACTION:
Notice.
The Diabetes Mellitus
Interagency Coordinating Committee
(DMICC) will hold a meeting on October
30, 2020. The topic for this meeting will
be ‘‘Health Literacy and Numeracy:
Considerations for Equity Approaches.’’
The meeting is open to the public.
DATES: The meeting will be held on
October 30, 2020 from 1 p.m. to 5:00
p.m. EDT.
ADDRESSES: The meeting will be held
via the online video conferencing—
Zoom. For details, and to register, please
contact dmicc@mail.nih.gov.
FOR FURTHER INFORMATION CONTACT: For
further information concerning this
meeting, including a draft agenda, see
the DMICC website,
www.diabetescommittee.gov, or contact
Dr. B. Tibor Roberts, Executive
Secretary of the Diabetes Mellitus
Interagency Coordinating Committee,
National Institute of Diabetes and
Digestive and Kidney Diseases, 31
Center Drive, Building 31A, Room
9A19, MSC 2560, Bethesda, MD 20892–
2560, telephone: 301–496–6623; FAX:
301–480–6741; email: dmicc@
mail.nih.gov.
SUPPLEMENTARY INFORMATION: In
accordance with 42 U.S. Code § 285c–3,
the DMICC, chaired by the National
Institute of Diabetes and Digestive and
Kidney Diseases (NIDDK) comprising
members of the Department of Health
and Human Services and other federal
agencies that support diabetes-related
activities, facilitates cooperation,
communication, and collaboration on
diabetes among government entities.
DMICC meetings, held several times a
year, provide an opportunity for
Committee members to learn about and
discuss current and future diabetes
programs in DMICC member
organizations and to identify
opportunities for collaboration. The
October 30, 2020 DMICC meeting will
focus on ‘‘Health Literacy and
SUMMARY:
E:\FR\FM\09OCN1.SGM
09OCN1
Agencies
[Federal Register Volume 85, Number 197 (Friday, October 9, 2020)]
[Notices]
[Page 64152]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2020-22370]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
Government-Owned Inventions; Availability for Licensing;
Correction
AGENCY: National Institutes of Health, HHS.
ACTION: Notice; correction.
-----------------------------------------------------------------------
SUMMARY: The Department of Health and Human Services, National
Institutes of Health published a Notice in the Federal Register on
October 1, 2020. That Notice requires a correction in the SUPPLEMENTARY
INFORMATION section.
FOR FURTHER INFORMATION CONTACT: Amy F. Petrik, Ph.D., licensing
contact, 240-627-3721; [email protected]. Licensing information and
copies of the U.S. patent application may be obtained by communicating
with the licensing contact at the Technology Transfer and Intellectual
Property Office, National Institute of Allergy and Infectious Diseases,
5601 Fishers Lane, Rockville, MD 20852; tel. 301-496-2644. A signed
Confidential Disclosure Agreement will be required to receive copies of
unpublished patent applications.
SUPPLEMENTARY INFORMATION:
Correction
In the Federal Register of October 1, 2020, in FR Doc. 2020-21708,
on page 61961, as found within the SUPPLEMENTARY INFORMATION section.
The title of the invention, currently reads ``Structure-Based Design of
SARS2-CoV-2 Spike Immunogens Stabilized in the RBD-All Down
Conformation'' and should read ``Structure-Based Design of SARS-CoV-2
Spike Immunogens Stabilized in the RBD-All Down Conformation''.
Dated: October 5, 2020.
Daniel R Hernandez,
Federal Register Officer, National Institutes of Health.
[FR Doc. 2020-22370 Filed 10-8-20; 8:45 am]
BILLING CODE 4140-01-P